TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner
Open Access
- 13 April 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 16 (4), e1008507
- https://doi.org/10.1371/journal.ppat.1008507
Abstract
The HIV-1 capsid protein makes up the core of the virion and plays a critical role in early steps of HIV replication. Due to its exposure in the cytoplasm after entry, HIV capsid is a target for host cell factors that act directly to block infection such as TRIM5α and MxB. Several host proteins also play a role in facilitating infection, including in the protection of HIV-1 capsid from recognition by host cell restriction factors. Through an unbiased screening approach, called HIV-CRISPR, we show that the CPSF6-binding deficient, N74D HIV-1 capsid mutant is sensitive to restriction mediated by human TRIM34, a close paralog of the well-characterized HIV restriction factor TRIM5α. This restriction occurs at the step of reverse transcription, is independent of interferon stimulation, and limits HIV-1 infection in key target cells of HIV infection including CD4+ T cells and monocyte-derived dendritic cells. TRIM34 can also restrict some SIV capsids. TRIM34 restriction requires TRIM5α as knockout or knockdown of TRIM5α results in a loss of antiviral activity. Through immunofluorescence studies, we show that TRIM34 and TRIM5α colocalize to cytoplasmic bodies and are more frequently observed to be associated with infecting N74D capsids than with WT HIV-1 capsids. Our results identify TRIM34 as an HIV-1 CA-targeting restriction factor and highlight the potential role for heteromultimeric TRIM interactions in contributing to restriction of HIV-1 infection in human cells. HIV-1 infection in humans is the result of cross-species transmission of a related primate lentivirus from chimpanzees. In order to adapt to replicate in human cells, HIV-1 adapted to host proteins that restrict infection by viruses. The HIV-1 capsid protein encapsidates the HIV-1 genome, allowing it to be delivered to the host cell for integration into the host chromosome. However, on delivery to the cytoplasm the HIV-1 capsid protein is exposed to an array of capsid-targeting restriction factors that act to limit infection. Viral mutants can be used to reveal some of these restriction factors. Our results show that TRIM34 is an antiviral effector that blocks infection of an HIV with a particular mutation in capsid. TRIM34 also inhibits some lentiviruses that infect monkeys. This block requires the closely-related paralog TRIM5α, a capsid-targeting restriction factor with well-characterized antiviral activity in primates. These results highlight the complex interaction between HIV-1 with human antiviral proteins.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI147877)
- Center for AIDS Research, University of Washington (AI027757)
- National Institute of Allergy and Infectious Diseases (R01 AI30927)
- National Institute of Allergy and Infectious Diseases (R37 AI147868)
- National Institute of Allergy and Infectious Diseases (R01 AI093258)
This publication has 53 references indexed in Scilit:
- Human Immunodeficiency Virus Type 1 Capsid Mutation N74D Alters Cyclophilin A Dependence and Impairs Macrophage InfectionJournal of Virology, 2012
- HIV Restriction Factors and Mechanisms of EvasionCold Spring Harbor Perspectives in Medicine, 2012
- Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleusRetrovirology, 2011
- Determinants of the Higher Order Association of the Restriction Factor TRIM5α and Other Tripartite Motif (TRIM) ProteinsOnline Journal of Public Health Informatics, 2011
- Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 proteinNature, 2011
- SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by VpxNature, 2011
- TRIM5 is an innate immune sensor for the retrovirus capsid latticeNature, 2011
- Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical TrialThe Journal of Infectious Diseases, 2010
- Flexible Use of Nuclear Import Pathways by HIV-1Cell Host & Microbe, 2010
- Discordant Evolution of the Adjacent Antiretroviral Genes TRIM22 and TRIM5 in MammalsPLoS Pathogens, 2007